Financing led by CARMA FUND and RV Invest with participation of High-Tech Gründerfonds and others Akribion is pioneering a   unique, RNA-guided, nuclease-based technology ...
Akribion Therapeutics ("Akribion"), the early-stage biotech developing a unique, RNA-guided, nuclease-based technology for programmable cell depletion, today announces its exit from stealth and the ...
After hours: February 3 at 4:21:39 PM EST Loading Chart for LXEO ...
After hours: February 7 at 6:36:04 PM EST Loading Chart for TENX ...
Sanofi S.A. Part Cert 0.02% €8.03M ...
5 February 2025 The US Food and Drug Administration (FDA) has approved Susvimo (ranibizumab injection) 100mg/mL for the treatment of diabetic macular edema (DME), said Swiss pharma giant Roche.